Catalysts for Opdivo

Chiba Cancer Center — nivolumab (Phase I/II Trial Completion)

Vanderbilt-Ingram Cancer Center — nivolumab (Phase I Trial Initiation)

Pt.Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences Rohtak — nivolumab (Phase II Trial Completion)

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval